Chronic Kidney Disease Market Report 2026

Chronic Kidney Disease Market Overview

• Chronic Kidney Disease market size has reached to $74.87 billion in 2025 • Expected to grow to $101.87 billion in 2030 at a compound annual growth rate (CAGR) of 6.4% • Growth Driver: The Rising Prevalence Of Kidney Disease Drives Growth In The Chronic Kidney Disease Market • Market Trend: Awak Technologies And Singapore General Hospital Forge Strategic Partnership To Revolutionize Kidney Dialysis With Awak Pd • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Chronic Kidney Disease Market?

Chronic kidney disease is characterized by the inability of damaged kidneys to efficiently filter blood, resulting in excess fluid and blood waste in the body, potentially leading to health problems. It is commonly caused by diabetes, high blood pressure, and obesity. It requires careful, ongoing management and has the potential to proceed to end-stage renal failure requiring dialysis or transplant. The main diagnostic tests for chronic kidney disease are blood tests, urine tests, imaging tests, and a kidney biopsy. A blood test refers to the scientific examination of a blood sample that will be examined medically. The various types of treatments include drugs, dialysis, kidney transplants, ACE inhibitors, blood tests, and others. These drugs are administered through oral, intravenous, and subcutaneous routes of administration, and are used by various end-users, such as hospitals and clinics, ambulatory surgery centers (ASCS), dialysis centers, and others.

What Is The Chronic Kidney Disease Market Growth Forecast?

The chronic kidney disease market size is expected to see strong growth in the next few years. It will grow to $101.87 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing development of novel renal therapies, rising demand for patient-centric dialysis options, expansion of digital kidney health monitoring, growing focus on transplant readiness, increasing investments in preventive nephrology. Major trends in the forecast period include increasing emphasis on early ckd detection, rising adoption of renoprotective drug therapies, growing use of home dialysis solutions, expansion of multidisciplinary care models, enhanced focus on slowing disease progression.

Global Chronic Kidney Disease Market Segmentation

1) By Diagnosis: Blood Test, Urine Test, Imaging Test, Kidney Biopsy 2) By Treatment: Drugs, Dialysis, Kidney Transplant, ACE Inhibitors, Blood Test, Other Treatments 3) By Route of Administration: Oral, Intravenous, Subcutaneous 4) By End-User: Hospital And Clinics, Ambulatory Surgery Centers (ASCs), Dialysis Centers, Other End-Users Subsegments: 1) By Blood Test: Serum Creatinine Test, Glomerular Filtration Rate (GFR) Test, Blood Urea Nitrogen (BUN) Test, Electrolyte Tests 2) By Urine Test: Urinalysis, 24-hour Urine Collection, Urine Protein Test, Urine Albumin-To-Creatinine Ratio (ACR) 3) By Imaging Test: Ultrasound, CT Scan, MRI, X-Ray 4) By Kidney Biopsy: Percutaneous Kidney Biopsy, Open Kidney Biopsy, Laparoscopic Kidney Biopsy

What Is The Driver Of The Chronic Kidney Disease Market?

The increasing prevalence of kidney disease is expected to propel the growth of the chronic kidney disease market going forward. Kidney diseases refer to a group of conditions that affect the function and structure of the kidneys. Medication for kidney disease is used to control blood pressure in patients and decrease protein loss to halt the progression of kidney impairment, manage symptoms, and avoid consequences. For instance, in June 2023, according to the Kidney Research UK, a UK-based, charity dedicated to funding research into kidney disease, by 2033, the population affected by CKD stages 3–5 is expected to rise to around 3.9 million. Therefore, the increasing prevalence of kidney disease is driving the growth of the chronic kidney disease industry.

Key Players In The Global Chronic Kidney Disease Market

Major companies operating in the chronic kidney disease market are Pfizer Inc, Johnson and Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott laboratories Inc., GlaxoSmithKline PLC, Takeda Pharmaceuticals Ltd., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Novo Nordisk AS, Siemens Healthineers AG, AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Beckman Coulter Inc., Kissei Pharmaceutical Co. Ltd., Akebia Therapeutics Inc., Tricida Inc., Regulus Therapeutics Inc., Goldfinch Bio Co, Alio Inc., Monogram Health, Strive Health, Maze Therapeutics, ProKidney Corp

Global Chronic Kidney Disease Market Trends and Insights

Major companies operating in the chronic kidney disease market are adopting a strategic partnership approach to study the safety and efficacy of an improved Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in June 2023, AWAK Technologies Pte Ltd., a Singapore-based medical technology company, partnered with Singapore General Hospital Pte Ltd. (SGH), a Singapore-based academic health science center and hospital company. With this partnership, they aim to revolutionize the diagnosis, treatment, and management of kidney disease and involve the development and testing of a wearable and ultra-portable peritoneal dialysis (PD) system, known as AWAK PD, which allows patients with end-stage kidney disease to undergo dialysis at home and on the go.

What Are Latest Mergers And Acquisitions In The Chronic Kidney Disease Market?

In January 2023, AstraZeneca Pharmaceuticals LP, a US-based biopharmaceutical company, acquired CinCor Pharma Inc. for $1.8 billion. The acquisition will add CinCor's candidate medicine, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure control in treatment-resistant hypertension, to AstraZeneca's cardiorenal pipeline. CinCor Pharma Inc. is a US-based clinical-stage biopharmaceutical company that develops products to treat resistant and uncontrolled hypertension and chronic kidney disease.

Regional Outlook

North America was the largest region in the chronic kidney disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chronic Kidney Disease Market?

The chronic kidney disease market consists of revenues earned by entities by providing peritoneal dialysis, in-center hemodialysis, and home hemodialysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic kidney disease market also includes sales such as captopril, enalapril, finerenone, and fosinopril used during the treatment procedure. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chronic Kidney Disease Market Report 2026?

The chronic kidney disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chronic kidney disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.